Title:
METHODS FOR TREATING PARKINSON'S DISEASE BY AN AGONIST D3 AND BDNF TRANSFECTION-COMBINATION THERAPY
Document Type and Number:
WIPO Patent Application WO/2015/087266
Kind Code:
A3
Abstract:
The present invention relates to the field of neurotrophic gene therapy and is based on genomics and nanotechnology in combination with a drug therapy, thereby promoting mitogenic, neurogenic, and neuritogenic events for the treatment of Parkinson's disease at any stage. More particularly, the invention comprises associating the systemic administration of a dopaminergic agonist D3 with BDNF gene transfection using NTS-polyplex macromolecular vector in dopaminergic neurons of the substantia nigra to promote the restoration of the nigrostriatal dopaminergic pathway in the treatment of Parkinson's disease.
Inventors:
RAZGADO HERNÁNDEZ LUIS FERNANDO (MX)
MARTÍNEZ FONG DANIEL (MX)
ACEVES RUÍZ JORGE (MX)
MARTÍNEZ FONG DANIEL (MX)
ACEVES RUÍZ JORGE (MX)
Application Number:
PCT/IB2014/066780
Publication Date:
November 12, 2015
Filing Date:
December 11, 2014
Export Citation:
Assignee:
CT DE INVESTIGACIÓN Y DE ESTUDIOS AVANZADOS DEL INST POLITÉCNICO NAC (MX)
International Classes:
C12N5/10; A61K31/135; A61K38/18; A61P25/16; C12N15/12
Other References:
DU F. ET AL.: "Dopamine D3 receptor-preferring agonists induce neurotrophic effects on mesencephalic dopamine neurons.", EUROPEAN JOURNAL OF NEUROSCIENCE., vol. 22, no. 10, November 2005 (2005-11-01), pages 2422 - 2430, XP055235608
VAN KAMPEN J. M. ET AL.: "Dopamine D3 Receptor Agonist Delivery to a Model of Parkinson's Disease Restores the Nigrostriatal Pathway and Improves Locomotor Behavior.", THE JOURNAL OF NEUROSCIENCE., vol. 26, no. 27, 5 July 2006 (2006-07-05), pages 7272 - 7280, XP055235609
SOKOLOFF P. ET AL.: "The Dopamine D3 Receptor: A Therapeutic Target for the Treatment of Neuropsychiatric Disorders.", CNS & NEUROLOGICAL DISORDERS - DRUG TARGETS., vol. 5, no. 1, February 2006 (2006-02-01), pages 25 - 43, XP055235610
CONNOR B. ET AL.: "The role of neuronal growth factors in neurodegenerative disorders of the human brain.", BRAIN RESEARCH REVIEWS., vol. 27, no. 1, June 1998 (1998-06-01), pages 1 - 39, XP002920051
MARTINEZ-FONG D. ET AL.: "NTS-Polyplex: a potential nanocarrier for neurotrophic therapy of Parkinson's disease.", NANOMEDICINE: NANOTECHNOLOGY, BIOLOGY, AND MEDICINE., vol. 8, no. 7, October 2012 (2012-10-01), pages 1052 - 1069, XP055097190
VAN KAMPEN J. M. ET AL.: "Dopamine D3 Receptor Agonist Delivery to a Model of Parkinson's Disease Restores the Nigrostriatal Pathway and Improves Locomotor Behavior.", THE JOURNAL OF NEUROSCIENCE., vol. 26, no. 27, 5 July 2006 (2006-07-05), pages 7272 - 7280, XP055235609
SOKOLOFF P. ET AL.: "The Dopamine D3 Receptor: A Therapeutic Target for the Treatment of Neuropsychiatric Disorders.", CNS & NEUROLOGICAL DISORDERS - DRUG TARGETS., vol. 5, no. 1, February 2006 (2006-02-01), pages 25 - 43, XP055235610
CONNOR B. ET AL.: "The role of neuronal growth factors in neurodegenerative disorders of the human brain.", BRAIN RESEARCH REVIEWS., vol. 27, no. 1, June 1998 (1998-06-01), pages 1 - 39, XP002920051
MARTINEZ-FONG D. ET AL.: "NTS-Polyplex: a potential nanocarrier for neurotrophic therapy of Parkinson's disease.", NANOMEDICINE: NANOTECHNOLOGY, BIOLOGY, AND MEDICINE., vol. 8, no. 7, October 2012 (2012-10-01), pages 1052 - 1069, XP055097190
Attorney, Agent or Firm:
CARREÑO SÁNCHEZ, Luis Antonio (no. 2508 Col. San Pedro Zacatenco,,Edificio Administrativo, 3er. piso, Subdirección de Vinculación Tecnológica,Méxic, D.F. ., MX)
Download PDF:
Previous Patent: DIRECT INTEGRATION OF FEEDTHROUGH TO IMPLANTABLE MEDICAL DEVICE HOUSING BY SINTERING
Next Patent: STABLE BROMFENAC OPHTHALMIC SOLUTION
Next Patent: STABLE BROMFENAC OPHTHALMIC SOLUTION